COMMUNIQUÉS West-GlobeNewswire

INNATE PHARMA : Résultats d'escalade de dose d'IPH4102 : Profil de tolérance et activité clinique prometteurs

15/06/2017 - 07:00

rÉsultats d'escalade de dose d'IPH4102 : profil de tolÉrance et activitÉ clinique prometteurs La partie en escalade de dose de l'essai de Phase I a fait l'objet d'une présentation orale lors de l'ICML [1] à Lugano ; [...]

Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan

15/06/2017 - 07:00

Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan Paris, France - June 15, 2017 - Sanofi announced today the launch of "Action 2017", a worldwide stock purchase plan reserved for its employees. In [...]

Sanofi lance « Action 2017 », un plan mondial d'actionnariat salarié

15/06/2017 - 07:00

Sanofi lance « Action 2017 », un plan mondial d'actionnariat salarié Paris, France - Le 15 juin 2017 - Sanofi annonce aujourd'hui le lancement d' « Action 2017 », un plan mondial d'actionnariat salarié. En procédant à [...]

Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel

14/06/2017 - 19:15

Press release (PDF) This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for [...]

SPINEWAY enregistre une nouvelle commande d'1 M$ aux USA

14/06/2017 - 18:15

Communiqué de presse Ecully, le 14 juin 2017 SPINEWAY enregistre une nouvelle commande d'1 M$ aux USA Spineway, spécialiste des implants et ancillaires chirurgicaux pour le traitement des pathologies de la colonne [...]

SPINEWAY records a new $1M order in the USA

14/06/2017 - 18:15

Press release Ecully, 14 June 2017 SPINEWAY records a new $1M order in the USA Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has obtained a new order via [...]

Guerbet investit dans le fonds de Truffle Capital dédié aux dispositifs médicaux et biotechnologies

14/06/2017 - 18:04

Villepinte, le 14 juin 2017 - 18:00 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale annonce avoir signé une prise de participation d'un montant de quinze [...]

Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies

14/06/2017 - 18:04

Villepinte, June 14, 2017 - 6:00 pm CEST - Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, today announced that it has signed an equity acquisition of fifteen [...]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

14/06/2017 - 18:00

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...

14/06/2017 - 18:00

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson

14/06/2017 - 17:35

ALLSCHWIL/BASEL, SWITZERLAND - 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss [...]

Ordinary General Meeting of Shareholders of Probiodrug AG

14/06/2017 - 16:40

Ordinary General Meeting of Shareholders of Probiodrug AG All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company [...]

Ordinary General Meeting of Shareholders of Probiodrug AG

14/06/2017 - 16:25

Ordinary General Meeting of Shareholders of Probiodrug AG All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company [...]

Silmäasema Oyj: 10 largest shareholders after the end of the Initial Public Offering

14/06/2017 - 15:30

Stock Exchange Release 14 June 2017, at 4.30 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]

Libelium presents a white paper with 50 real IoT success stories after ten years of experience in the market

14/06/2017 - 15:00

The IoT company summarizes 50 of the most successful projects developed with its wireless sensor platform for smart cities, agriculture, water, logistics, parking, eHealth or environment industries. Zaragoza (Spain), 14 [...]

Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

14/06/2017 - 14:45

Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability and efficacy of [...]

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis

14/06/2017 - 14:00

The positive Phase III top-line results indicate that the study successfully met its primary endpoint and BEKINDA ® 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and [...]

Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label

14/06/2017 - 13:03

Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba ® (insulin degludec) [...]

Summit Therapeutics plc : 1st Quarter Results

14/06/2017 - 13:00

Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 - Summit [...]